# Inovio Pharmaceuticals clinical trials: 31 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Inovio Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Inovio Pharmaceuticals: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/inovio-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 24, 2022 | NCT05430958 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers | Inovio Pharmaceuticals | Phase 1 | Withdrawn | Coronavirus Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05430958) |
| November 24, 2020 | NCT04642638 | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure | Inovio Pharmaceuticals | Phase 2/3 | Terminated | Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease | 1,307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04642638) |
| October 19, 2020 | NCT04588428 | Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers | Inovio Pharmaceuticals | Phase 2 | Completed | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04588428) |
| May 21, 2020 | NCT04398433 | INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) | Inovio Pharmaceuticals | Phase 1/2 | Completed | Respiratory Papillomatosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04398433) |
| April 7, 2020 | NCT04336410 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | Inovio Pharmaceuticals | Phase 1 | Completed | Coronavirus Infection | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04336410) |
| September 17, 2019 | NCT04093076 | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana | Inovio Pharmaceuticals | Phase 1 | Completed | Lassa Fever | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04093076) |
| January 16, 2019 | NCT03805984 | Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | Inovio Pharmaceuticals | Phase 1 | Completed | Lassa Fever | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03805984) |
| October 26, 2018 | NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Inovio Pharmaceuticals | Phase 3 | Completed | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03721978) |
| April 19, 2018 | NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | Inovio Pharmaceuticals | Phase 1/2 | Completed | Urothelial Carcinoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03502785) |
| April 17, 2018 | NCT03499795 | VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or... | Inovio Pharmaceuticals | Phase 2 | Completed | Anal Neoplasm | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03499795) |
| April 9, 2018 | NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | Inovio Pharmaceuticals | Phase 1/2 | Active not recruiting | Glioblastoma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03491683) |
| June 14, 2017 | NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Inovio Pharmaceuticals | Phase 3 | Completed | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03185013) |
| June 8, 2017 | NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar... | Inovio Pharmaceuticals | Phase 2 | Completed | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN)... | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03180684) |
| November 9, 2016 | NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Inovio Pharmaceuticals | Phase 1 | Completed | Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer... | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02960594) |
| August 3, 2015 | NCT02514213 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | Inovio Pharmaceuticals | Phase 1 | Completed | Prostate Cancer | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02514213) |
| June 8, 2015 | NCT02464670 | Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers | Inovio Pharmaceuticals | Phase 1 | Completed | Ebola Vaccine | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02464670) |
| May 1, 2015 | NCT02431312 | Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects | Inovio Pharmaceuticals | Phase 1 | Completed | Hepatitis B | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431312) |
| September 16, 2014 | NCT02241369 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies | Inovio Pharmaceuticals | Phase 1 | Completed | Aerodigestive Precancerous Lesions and Malignancies | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02241369) |
| June 24, 2014 | NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | Inovio Pharmaceuticals | Phase 1/2 | Completed | Cervical Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02172911) |
| June 13, 2014 | NCT02163057 | Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma | Inovio Pharmaceuticals | Phase 1/2 | Completed | Head and Neck Squamous Cell Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02163057) |
| July 29, 2011 | NCT01405885 | A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus | Inovio Pharmaceuticals | Phase 1 | Completed | Healthy | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01405885) |
| July 27, 2011 | NCT01403155 | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 | Inovio Pharmaceuticals | Phase 1 | Completed | Healthy | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01403155) |
| February 25, 2011 | NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 | Inovio Pharmaceuticals | Phase 2 | Completed | Cervical Intraepithelial Neoplasia | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01304524) |
| August 26, 2010 | NCT01188850 | Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 | Inovio Pharmaceuticals | Phase 1 | Completed | Human Papillomavirus (HPV) | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01188850) |
| June 11, 2010 | NCT01142362 | Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults | Inovio Pharmaceuticals | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01142362) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 5 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Terminated | 3 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 5 |
| Coronavirus Infections | 4 |
| Uterine Cervical Neoplasms | 4 |
| Head and Neck Neoplasms | 4 |
| Uterine Cervical Dysplasia | 3 |
| Squamous Intraepithelial Lesions | 3 |
| Carcinoma, Squamous Cell | 3 |
| COVID-19 | 2 |
| Lassa Fever | 2 |
| Influenza in Birds | 2 |
| Carcinoma | 2 |
| Papillomavirus Infections | 1 |
| HIV Infections | 1 |
| Prostatic Neoplasms | 1 |
| Hepatitis B | 1 |
| Influenza, Human | 1 |
| Breast Neoplasms | 1 |
| Lung Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Ovarian Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
| Laryngeal Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Structural engineering firms in the United States](https://specstream.ai/data/businesses/structural-engineering-firms/united-states)
- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Environmental testing companies in the United States](https://specstream.ai/data/businesses/environmental-testing-companies/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
